Studies show that 9 out of 10 patients who thought they were allergic to penicillin are.

The over-use of wide spectrum antibiotics decreases antibiotic effectiveness and will increase the development of drug-resistant germs according to the Centers for Disease Control and Avoidance . According to the CDC antibiotic level of resistance is one of the world’s most pressing general public health threats. Related StoriesMany seasonal allergy victims take OTC products rather prescription medicationsNew research uncovers antibiotic prescription styles across EnglandMajority of individuals not allergic to intravenous penicillins, state ACAAI allergistsTesting for the true presence of a penicillin allergy is crucial in helping decrease the number of patients who self-report as being penicillin allergic but don’t have a genuine penicillin allergy .

‘Completing the scientific trial and regulatory submitting for the CE tag had been significant achievements for our organization last year. Our ability to secure this most recent financing in an interval of just four weeks reflects the confidence of our investors in the potential of the Hemolung RAS to produce a true difference in the lives of patients suffering from acute respiratory failure.’ Individuals in the funding included existing shareholders, co-traders of Eagle Ventures, and Birchmere Ventures. ‘We continue to be very excited about ALung and the Hemolung technology,’ said Gary Glausser, Partner at Birchmere Ventures, a Pittsburgh-based early-stage capital raising company that bolstered its investment in ALung through the Series B circular. ‘The Hemolung device may be the first truly new option for patients with acute respiratory failure in many years and ALung proceeds to make great improvement toward commercializing the product.’..